Edition:
United States

Pfizer says U.S. FDA and EMA accept regulatory submissions for bosuliffor


Tuesday, 29 Aug 2017 07:00am EDT 

Aug 29 (Reuters) - Pfizer Inc :U.S. FDA and European Medicines Agency accept regulatory submissions for Bosulif® (bosutinib) for the treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia.Says ‍prescription drug user fee act (PDUFA) goal date for a decision by FDA is in December 2017​.